> Chemicals & Drugs > Organic Chemical > Docetaxel

Docetaxel

Most cited protocols related to «Docetaxel»

Metastatic Prostate Cancer Treatment Protocol

Cited 37 times

Patients were enrolled by ECOG-ACRIN, the Southwest Oncology Group, the Alliance for Clinical Trials in Oncology, and NRG Oncology (a merged group that includes the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group) and through the Clinical Trials Support Unit. Eligible patients had a pathological diagnosis of prostate cancer or a clinical scenario consistent with prostate cancer with an elevated prostate-specific antigen (PSA) level; radiologic evidence of metastatic disease; and an ECOG performance-status score of 0, 1, or 2 (on a scale from 0 to 5, with higher scores indicating greater disability; patients with a score of 2 were eligible if the decrement in functioning was due to prostate cancer). Prior adjuvant ADT was allowed if the duration of therapy was 24 months or less and progression had occurred more than 12 months after completion of therapy. Patients who were receiving ADT for meta-static disease were eligible if there was no evidence of progression and treatment had commenced within 120 days before randomization. Organ function that was adequate for docetaxel treatment was required (details are provided in the protocol). All patients provided written informed consent in accordance with institutional and federal guidelines.

Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M., Wong Y.N., Hahn N., Kohli M., Cooney M.M., Dreicer R., Vogelzang N.J., Picus J., Shevrin D., Hussain M., Garcia J.A, & DiPaola R.S. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine, 373(8), 737-746.

Publication 2015

Breast Diagnosis Disabled Persons Disease Progression Docetaxel Electrocorticography Intestines Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Pharmaceutical Adjuvants Prostate-Specific Antigen Prostate Cancer

PD-L1 Expression Directed Atezolizumab vs Docetaxel

Cited 33 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016

atezolizumab Biological Assay CD274 protein, human Cells Docetaxel Gene Expression Immunohistochemistry Neoplasms Patients Pharmacotherapy Tissues Treatment Protocols

Lipid-Polymer Hybrid Nanoparticle Fabrication

Cited 29 times

Lipid-polymer hybrid NPs were prepared via self-assembly of PLGA (poly (D,L-lactic-co-glycolic acid); Lactel, Pelham, AL), lecithin (soybean, refined, molecular weight: ~330 Da; Alfa Aesar, Ward Hill, MA), and DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine- N-carboxy (polyethylene glycol)2000); Avanti, Alabaster, AL) through a single-step nanoprecipitation method. Briefly, PLGA polymer was dissolved in acetonitrile with concentrations ranging from 1~5 mg/mL. Lecithin/DSPE-PEG (8.5/1.5, molar ratio) with a weight ratio of 15% to the PLGA polymer were dissolved in 4 wt% ethanol aqueous solution. The lecithin/DSPE-PEG solution was heated to 65°C to ensure all lipids were in liquid phase. The resulting PLGA solution was then added into the preheated lipid solution dropwise under gentle stirring. The mixed solution was vortexed vigorously for 3 minutes followed by gentle stirring for 2 hours at room temperature. The remaining organic solvent and free molecules were removed by washing the NP solution three times using an Amicon Ultra-4 centrifugal filter (Millipore, Billerica, MA) with a molecular weight cut-off of 10,000 Da. To prepare drug-encapsulated NPs, docetaxel (Sigma-Aldrich, St Louis, MO) with proper initial dosage was dissolved into the PLGA acetonitrile solution before the nanoprecipitation process. NP size (diameter, nm) and surface charge (zeta potential, mV) were obtained from three repeat measurements by Quasi-elastic laser light scattering with a ZetaPALS dynamic light scattering detector (15 mW laser, incident beam = 676 nm; Brookhaven Instruments Corporation, Holtsville, NY).

Zhang L., Chan J.M., Gu F.X., Rhee J.W., Wang A.Z., Radovic-Moreno A.F., Alexis F., Langer R, & Farokhzad O.C. (2008). Self-Assembled Lipid-Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform. ACS nano, 2(8), 1696-1702.

Publication 2008

1,2-distearoylphosphatidylethanolamine acetonitrile Alabaster DA10 Docetaxel Ethanol glycolic acid Hybrids Lecithin Lipids Molar Pharmaceutical Preparations Phosphatidylethanolamines Poly A polyethylene glycol 2000 Polylactic Acid-Polyglycolic Acid Copolymer Polymers Solvents Soybeans

Reproducible Bioinformatics Analysis Pipeline

Cited 23 times

Annotated R code (in Sweave format) to reproduce all of the analysis in this paper is available from our website [57 ]. The CGP gene expression data are available from ArrayExpress under accession number E-MTAB-783. The IC₅₀ data for the drugs is available from the CGP website [52 ]. The docetaxel data are available from GEO under accession numbers [GEO:GSE349] and [GEO:GSE350]. The cisplatin data are available from ArrayExpress under accession number E-GEOD-18864. The bortezomib data are available from GEO under accession number [GEO:GSE9782]. The erlotinib data are available from GEO under accession number [GEO:GSE33072]. Complete details and R code showing how to acquire and preprocess all of these data, as well as the associated clinical data are available in Sweave format on our website.

Geeleher P., Cox N.J, & Huang R.S. (2014). Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biology, 15(3), R47.

Full text: Click here

Publication 2014

Bortezomib Cisplatin Docetaxel Erlotinib Gene Expression Pharmaceutical Preparations

Tracking TNBC Response to Neoadjuvant Chemo

Cited 16 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2018

Bevacizumab Core Needle Biopsy Docetaxel Epirubicin Fishes Freezing Immunohistochemistry Inflammatory Breast Carcinoma Lymph Node Metastasis Malignant Neoplasm of Breast Malignant Neoplasms Neoplasms Operative Surgical Procedures Patients Tissues Triple Negative Breast Neoplasms

Most recents protocols related to «Docetaxel»

Docetaxel Prodrug Cytotoxicity Assay

Not available on PMC !

Example 14

The docetaxel prodrug, synthesized as illustrated in FIG. 18A or B was administered to 2F2B cells in an alamar blue assay to measure metabolic activity. FIG. 22 shows a comparison between an αvβ3 targeted particle without docetaxel, an αvβ3 targeted particle with docetaxel, and an αvβ3 targeted particle with a docetaxel prodrug. As the assay progressed, the particle comprising the prodrug demonstrated a sustained suppression of cell metabolic activity, as compared to the targeted control without docetaxel.

US11872313B2. Prodrug compositions, prodrug nanoparticles, and methods of use thereof (2024-01-16). Washington University [US]. Inventors: Gregory M. Lanza [US], Dipanjan Pan [US].

Full text: Click here

Patent 2024

Alamar Blue Biological Assay Cells Docetaxel Prodrugs

Enhancing Anti-Cancer Activity in Brain Cancers

Not available on PMC !

Example 7

An amount of any one of the compounds of the present invention in combination with an anti-cancer agent is administered to a subject afflicted with brain cancer. The amount of the compound is effective to enhance the anti-cancer activity of the anti-cancer agent.

An amount of any one of the compounds of the present invention in combination with ionizing radiation, x-radiation, docetaxel or temozolomide is administered to a subject afflicted with brain cancer. The amount of the compound is effective to enhance the anti-cancer activity of the ionizing radiation, x-radiation, docetaxel or temozolomide.

An amount of any one of the compounds of the present invention in combination with an anti-cancer agent is administered to a subject afflicted with diffuse intrinsic pontine glioma or glioblastoma multiforme. The amount of the compound is effective to enhance the anti-cancer activity of the anti-cancer agent.

An amount of any one of the compounds of the present invention in combination with ionizing radiation, x-radiation, docetaxel or temozolomide is administered to a subject afflicted with diffuse intrinsic pontine glioma or glioblastoma multiforme. The amount of the compound is effective to enhance the anti-cancer activity of the ionizing radiation, x-radiation, docetaxel or temozolomide.

US11866444B2. Oxabicycloheptane prodrugs (2024-01-09). Lixte Biotechnology, Inc. [US]. Inventors: John S. Kovach [US], Robert A. Volkmann [US], Anthony Marfat [US].

Full text: Click here

Patent 2024

Brain Neoplasm, Malignant Diffuse Intrinsic Pontine Glioma Docetaxel Glioblastoma Multiforme Malignant Neoplasms Radiation, Ionizing Roentgen Rays Temozolomide

Chemotherapy Regimens for Advanced NSCLC

We retrospectively enrolled 278 patients diagnosed with advanced NSCLC who regularly received DP (docetaxel plus cisplatin), GP (gemcitabine plus cisplatin), NP (vinorelbine plus cisplatin), PC (pemetrexed plus cisplatin) and TP (paclitaxel plus cisplatin) chemotherapy regimens at the Affiliated Hospital of Xu Zhou Medical University from January May 2012 and July 2020.
The inclusion criteria were as follows: (1) NSCLC was pathologically diagnosed; (2) NSCLC was stage III or IV according to the American Joint Committee on Cancer (AJCC) 8th edition; (3) the patient received chemotherapy for more than two cycles without a combination of targeted therapy, radiation therapy and immune therapy; (4) the patient had no other cancer history and laboratory test results were obtained before treatment.
The exclusion criteria were as follows: (1) patients with missing or incomplete data; (2) patients who underwent surgery, radiotherapy, immunotherapy before standard chemotherapy protocols, (3) patients who had obvious fever and pneumonia before chemotherapy.
This retrospective study was approved by the ethics committee of the Affiliated Hospital of Xu Zhou Medical University.

Zhang Y., Kong F.F., Zhu Z.Q, & Shan H.X. (2023). Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy. BMC Cancer, 23, 225.

Full text: Click here

Publication 2023

Antineoplastic Chemotherapy Protocols Cisplatin Combined Modality Therapy Docetaxel Ethics Committees, Clinical Fever Gemcitabine Immunotherapy Joints Malignant Neoplasms Non-Small Cell Lung Carcinoma Operative Surgical Procedures Patients Pharmacotherapy Pneumonia Radiotherapy TP protocol Treatment Protocols Vinorelbine

Extracting and Modeling Survival Data

We used GetData Graph Digitizer (v2.26, http://getdata.sourceforge.net/download.html) to extract survival data from published PFS and OS Kaplan-Meier curves. To reconstruct individual patient data, we used the Guyot's method, which is the most accurate data reproduction method currently known for cases where individual patient data are not available (35 , 36 (link)). Log cumulative hazards and schoenfeld residual test plots (Supplementary material 2) showed proportional hazard (PH) or piecewise models were not suitable in this analysis. In accordance with the shapes of the survival curves, the non-PH NMA models considered in this study were first- and second-order fractional polynomial (FP) models (37 (link)). We fitted first- and second-order FP models with power parameters −2, −1, −0.5, 0, 0.5, 1, 2, and 3, with three parallel Markov chains consisting of 10,000 samples after a 10,000 samples burn-in. To reconstruct and extrapolate the PFS curve of the standard chemotherapy, and the OS and PFS curves of the second-line docetaxel, we considered parametric functions including Exponential, Weibull, Gompertz, Gamma, Log-logistic, Log-normal, Generalized Gamma, GenF, FP, Restricted Cubic Spline, and Royston and Parmar (RP) models. Goodness-of-fit was evaluated by visual inspection of survival curves, Akaike information criterion (AIC) and deviance information criterion (DIC). Lower AIC and DIC combined with reasonable visual effects indicated a better performance of the selected model (38 ). Survival modeling was conducted in R (v4.1.2) and Winbugs (v1.4.3) (39 , 40 ). R codes for relative methods can be found on Github (https://github.com/TaihangShao/NMA_methodology).

Zhao M., Shao T., Chi Z, & Tang W. (2023). Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. Frontiers in Public Health, 11, 1051484.

Full text: Click here

Publication 2023

Cuboid Bone Docetaxel Gamma Rays Patients Pharmacotherapy Reproductive Techniques

Comparative Evaluation of First-Line and Second-Line Treatments

In addition to exploring the optimal treatment sequences, we also conducted subgroup analysis of the cost-effectiveness between first-line or second-line treatments. For the first-line subgroup, we compared seven treatments (standard chemotherapy, N + C, P + C, T + C, CA + C, SI + C or SU + C); For the second-line subgroup, we compared three treatments (nivolumab, tislelizumab, and docetaxel).

Full text: Click here

Publication 2023

Docetaxel Nivolumab Pharmacotherapy tislelizumab

Top products related to «Docetaxel»

Docetaxel by Merck Group

Sourced in United States, Germany, China, United Kingdom, Italy, Japan, Canada

Docetaxel is a synthetic compound used in various laboratory applications. It is a member of the taxane class of antineoplastic agents. Docetaxel functions by disrupting the normal operation of cellular microtubules, which are essential for cell division and proliferation.

Docetaxel by Selleck Chemicals

Sourced in United States, Germany, China

Docetaxel is a cytotoxic agent used in the production of various pharmaceutical formulations. It functions as a microtubule-stabilizing agent, which can inhibit cell division and proliferation. Docetaxel is commonly used as a reference standard in analytical methods for the identification and quantification of this compound.

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Paclitaxel by Merck Group

Sourced in United States, Germany, United Kingdom, France, China, Macao, Japan, Sao Tome and Principe, Canada, Poland, Spain, Israel, Australia, Switzerland, Italy

Paclitaxel is a pharmaceutical compound used in the production of various cancer treatment medications. It functions as a microtubule-stabilizing agent, which plays a crucial role in the development and regulation of cells. Paclitaxel is a key ingredient in the manufacture of certain anti-cancer drugs.

Cisplatin by Merck Group

Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal

Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Docetaxel by LC Laboratories

Sourced in United States

Docetaxel is a cytotoxic agent used in the treatment of various types of cancer. It is a semi-synthetic taxane derivative that acts as a microtubule-stabilizing agent, inhibiting cell division and promoting apoptosis in rapidly dividing cells.

Docetaxel by Sanofi

Sourced in France, United Kingdom, United States, Canada, Japan

Docetaxel is a chemotherapy medication used in the treatment of various types of cancer. It is a type of taxane drug that works by interfering with the normal function of cell microtubules, thereby preventing cell division and growth.

Doxorubicin by Merck Group

Sourced in United States, Germany, United Kingdom, France, China, India, Italy, Poland, Macao, Japan, Sao Tome and Principe, Canada, Spain, Brazil, Australia, Belgium, Switzerland, Singapore, Israel

Doxorubicin is a cytotoxic medication that is commonly used in the treatment of various types of cancer. It functions as an anthracycline antibiotic, which works by interfering with the DNA replication process in cancer cells, leading to their destruction. Doxorubicin is widely used in the management of different malignancies, including leukemia, lymphoma, and solid tumors.

Du145 by American Type Culture Collection

Sourced in United States, United Kingdom, China, France, Germany, Sweden, Canada, Australia, Japan

The DU145 is a laboratory cell line derived from a human prostate carcinoma. It is widely used in cancer research for the study of cell biology and the development of potential therapies.

What are the common applications of Docetaxel in cancer treatment?

Docetaxel is a widely used chemotherapeutic agent that is commonly used to treat a variety of solid tumors, including breast, lung, ovarian, and prostate cancers. It works by promoting the assembly of microtubules and inhibiting their disassembly, resulting in cell-cycle arrest and apoptosis. Docetaxel's mechanism of action, pharmacokinetics, and clinical efficacy have been extensively studied, making it a valuable tool in the fight against cancer.

What are some of the key challenges in using Docetaxel effectively?

One of the main challenges with Docetaxel is optimizing the treatment protocols to ensure maximum efficacy and minimize side effects. Researchers often need to compare different Docetaxel formulations, dosages, and administration schedules to determine the most effective approach for their specific research goals. Additionally, Docetaxel can interact with other medications, so careful consideration of potential drug interactions is important.

How can PubCompare.ai help with Docetaxel research?

PubCompare.ai allows researchers to screen protocol literature more efficiently and leverage AI to pinpoint critical insights. The platform's AI-driven analysis can highlight key differences in protocol effeciveness, enabling researchers to choose the best option for reproducibility and accuracy. This can be particularly helpful when identifying the most effective products and protocols related to Docetaxel for your specific research goals.

Are there different formulations or types of Docetaxel available?

Yes, there are several different formulations of Docetaxel available, each with their own unique characteristics. For example, there are both branded and generic versions of Docetaxel, as well as different salt forms and delivery mechanisms (e.g., intravenous, oral). Researchers may need to evaluate the pros and cons of these different Docetaxel types to determine the best option for their stuides. PubCompare.ai can help by comparing the effectiveness of these different Docetaxel products across the literature.

How can PubCompare.ai help researchers leverage reproducible science for Docetaxel studies?

One of the key benefits of using PubCompare.ai for Docetaxel research is its ability to help researchers leverage reproducible science. The platform's AI-powered capabilities allow you to seach across a wide range of literature, preprints, and patents to locate the best protocols and identify the most effective products for your Docetaxel studies. This can improve the reproducibility and accuracy of your research by ensuring you're using the most optimized and validated protocols and products.

More about "Docetaxel"

Docetaxel, a widely used chemotherapeutic agent, is a semisynthetic taxoid that promotes the assembly of microtubules and inhibits their disassembly, resulting in cell-cycle arrest and apoptosis.
This potent antineoplastic drug is commonly used to treat a variety of solid tumors, including breast, lung, ovarian, and prostate cancers.
Docetaxel's mechanism of action, pharmacokinetics, and clinical efficacy have been extensively studied, making it a valuable tool in the fight against cancer.
Paclitaxel, another taxoid, is another commonly used chemotherapeutic agent that shares a similar mechanism of action with Docetaxel.
Both drugs are used to treat a variety of cancers, including breast, lung, and ovarian cancer.
Cisplatin, a platinum-based chemotherapeutic, is also often used in combination with Docetaxel or Paclitaxel to enhance their effectiveness.
Fetal bovine serum (FBS) is a commonly used supplement in cell culture media, providing essential nutrients and growth factors for cell proliferation.
DMSO, on the other hand, is a versatile solvent used to dissolve various compounds, including chemotherapeutic drugs like Doxorubicin, which is used to treat a variety of cancers.
Optimizing Docetaxel protocols and identifying the most effective products for related studies can be facilitated by the AI-powered capabilities of PubCompare.ai, which enables searching across literature, preprints, and patents to locate the best protocols and leverage reproducible science.
This can help researchers in the field of oncology to more efficiently and effectively conduct their studies, leading to advancements in cancer treatment and improved patient outcomes.